新冠疫苗有了新进展

US biotech firm Moderna reported promising early results on Monday from the first clinical tests of an experimental vaccine against the novel coronavirus performed on a small number of volunteers.

美国生物科技公司Moderna周一汇报说，他们对少数志愿者进行了新冠病毒实验性疫苗的首次临床测试，初步结果令人鼓舞。

The Cambridge, Massachusetts-based company said the vaccine candidate, mRNA-1273, appeared to produce an immune response in eight people who received it similar to that seen in people convalescing from the virus.

这家位于马萨诸塞州剑桥市的公司说候选疫苗mRNA-1273在8个接种疫苗的人体内产生了免疫反应，和康复的患者体内的反应差不多。

"These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection," said Moderna's chief medical officer Tal Zaks.

Moderna公司首席医务官Tal Zaks说：“这些暂时获得的第一阶段数据虽然是早期数据，但证明了接种mRNA-1273疫苗会产生和自然感染相同的免疫反应。”

"These data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials," Zaks said.

Zaks说：“这些数据证实了我们的想法，那就是mRNA-1273可以预防新冠肺炎，而且提高了我们选择关键试验剂量的能力。”

President Donald Trump welcomed the news saying "it's incredible what they can do and I've seen results. "And the results are staggeringly good," Trump told reporters. "So I'm very happy and the market's up very big."

唐纳德·特朗普总统听到这个消息很高兴，他说：“他们的能力令人难以置信，我也看到了他们的成绩，并且成绩喜人。”特朗普对记者说：“所以我很高兴，而且市场需求量很大。”

Wall Street stocks posted substantial gains on Monday with the Dow Jones Industrial Average adding 3.85 percent and the S&P 500 up 3.15 percent. Moderna shares gained 19.96 percent to close at US$80.00 in New York.

周一华尔街股市大幅上涨，道琼斯工业平均指数上涨3.85%，标准普尔500指数上涨3.15%。Moderna公司股票上涨了19.96%，在纽约以80.00美元的价格收盘。

Moderna, which was founded nine years ago, said the vaccine "was generally safe and well tolerated" and that patients suffered no more than redness or soreness from the shots.

九年前成立的Moderna公司称这种疫苗“总体上很安全、耐受性很好”，接种后只会出现红肿或疼痛。